World Immunization Week 2016 is April 24--30. Coincidentally, on April 4 the Philippines launched a dengue immunization program targeting more than 1 million schoolchildren using the world\'s first dengue vaccine, CYD-TDV (Dengvaxia®). It took more than 20 years of research and development, including two Phase 3 clinical trials involving over 35,000 participants aged 2--16 years, for this new vaccine to reach approval---first in Mexico, the Philippines and Brazil in December 2015, then El Salvador in February 2016, with several other countries in the process of regulatory review.

Over the past five decades, from being present in only a few countries, dengue is now endemic in more than 100 tropical and subtropical countries and is a major public health problem in Asia, Latin America and Africa. The World Health Organization (WHO) reports an estimated 390 million dengue infections every year, with 500,000 hospitalizations and 25,000 deaths. The causative agent, dengue virus, exists in four serotypes. Recovery from infection with one serotype usually results in lifelong immunity against that serotype, but not the others, while subsequent infections with other serotypes can lead to severe dengue, including the life-threatening dengue hemorrhagic fever. One possible explanation is antibody-dependent enhancement (ADE) when non-neutralizing antiviral antibodies help the virus gain entry into host cells and increase viral infectivity, although other immune components may also play a role. It is thus crucial for a dengue vaccine to induce immunity against all four serotypes concurrently.

CYD-TDV is a live attenuated, tetravalent, chimeric vaccine that is built on the backbone of the yellow fever 17D vaccine strain, which has been commercially available since the 1950s. Using DNA recombination technology, the pre-membrane (*prM*) and envelope (*E*) genes of 17D strain are replaced with those from each of the four dengue serotypes. In clinical trials, CYD-TDV was capable of inducing immunity against all four dengue serotypes, and resulted in 80% reduction in hospitalization and 90% reduction in severe dengue.

Dengue virus and yellow fever virus both belong to the genus *Flavivirus* that also includes West Nile virus (WNV) and Zika virus (ZIKV)---all of which can be transmitted by the mosquito *Aedes aegypti* that thrives in tropical and subtropical climates worldwide. There is only one ZIKV serotype, but unlike dengue, less is known about ZIKV pathogenesis. Because ZIKV infections generally produce mild influenza-like symptoms, the disease has been neglected for decades until the recent major outbreaks when the virus was suspected of being linked to serious neurological disorders, including Guillain--Barré syndrome (GBS) and fetal microcephaly. The current ZIKV outbreak started in 2015 in Brazil, spread quickly to several countries in Latin America, and is predicted to reach most of the Americas later in 2016. The WHO declared a global emergency in February 2016, and several research groups have rushed into developing a Zika vaccine. Due to the lack of ZIKV basic research, there are many unanswered questions when it comes to developing Zika vaccines. Which animal models are suitable to test such vaccines? Which immune surrogate markers can be used to assess vaccine efficacy? Can anti-ZIKV antibodies result in ADE and facilitate cellular infectivity of other flaviviruses, or increase the chance of developing autoimmune GBS? If a vaccine candidate becomes available too late after the current ZIKV epidemic has subsided, how can we measure its effectiveness in the population?

Fortunately previous groundwork on other flaviviruses, in particular WNV, could provide useful insights and directions in ZIKV research. The US National Institutes of Health (NIH) has previously developed a WNV vaccine candidate, which is a plasmid DNA expressing PrM/E glycoprotein of WNV strain NY99. NIH researchers now use the same plasmid vector but with *prM*/*E* genes from ZIKV to create a new Zika vaccine candidate. Human clinical trials of this DNA vaccine are scheduled to start in late summer 2016---one of the fastest timelines in vaccine research.

Despite the knowledge gap about ZIKV neuropathogenesis and the imminent spread of the virus into the US in summer 2016, President Obama\'s request of \$1.9 billion in emergency response funds is being locked in a congressional debate. In the UK, the government has trebled its ZIKV research funding to £3 million, with a further £1 million from the Wellcome Trust. Funding for vaccine research is vital and requires all stakeholders, from governmental and private funding bodies to the pharmaceutical industry, to understand medical needs and prioritize research directions.

Beyond science, funding and regulatory approval, a vaccine cannot succeed without public acceptance and engagement. Cultural and religious barriers need to be overcome, and scientifically clear communication about the vaccine\'s benefits and potential side effects is crucial. In resource-limited countries where mosquito-transmitted flaviviral infections are prevalent, logistical issues to ensure vaccines reach remote areas can present another hurdle. Bridging this gap in vaccine deployment is essential to the success of an immunization campaign and safeguards the protection of the community from infections.

The theme of this year\'s World Immunization Week is "Closing the Immunization Gap". While the recent approval of CYD-TDV is welcomed news, much more work remains to be done before the vaccine is fully integrated into health care systems and a reduction in global dengue burden can be demonstrated. Failure to close the gaps in scientific knowledge, funding and heath care practice could jeopardize our position in the fights against flaviviral diseases like dengue and Zika, as well as other infectious diseases.
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